Population pharmacokinetics of rifapentine and its primary desacetyl metabolite in South African tuberculosis patients

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 11, 2005, Pages 4429-4436

  Langdon, Grant ^a,b   Wilkins, Justin ^a,b   McFadyen, Lynn ^c   McIlleron, Helen ^a,d   Smith, Peter ^a   Simonsson, Ulrika S H ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b Biomedicum   (Sweden)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

25 DEACETYLRIFAPENTINE; DRUG METABOLITE; ETHAMBUTOL; INH BETABS; ISONIAZID; PRIFITIN; PYRAZIDE; PYRAZINAMIDE; RIFAFOUR; RIFAMPICIN; RIFAPENTINE; ROLAB;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; FEMALE; HUMAN; LUNG TUBERCULOSIS; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; SOUTH AFRICA;

ADULT; ANTIBIOTICS, ANTITUBERCULAR; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; RIFAMPIN; TUBERCULOSIS, PULMONARY;

EID: 27644435474     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.11.4429-4436.2005     Document Type: Article

References (22)

1. Acocella, G. 1978. Clinical pharmacokinetics of rifampicin. Clin. Pharmacokinet. 3:108-127.
2. American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America. 2003. Official joint statement on the treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 167:603-662.
3. Aventis Pharmaceuticals. 2000. Priftin package insert. Aventis Pharmaceuticals, Midrand, South Africa.
4. 14C-rifabutin in animals and man. J. Antimicrob. Chemother. 26:813-822.
5. Ette, E. I. 1997. Stability and performance of a population pharmacokinetic model. J. Clin. Pharmacol. 37:486-495.
6. Holford, N. H., and K. E. Peace. 1992. Results and validation of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. Proc. Natl. Acad. Sci. USA 89:11471-11475.
7. Jonsson, E. N., and M. O. Karlsson. 1999. Xpose: an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput. Methods Programs Biomed 58:51-64.
8. Kenny, M. T., and B. Strates. 1981. Metabolism and pharmacokinetics of the antibiotic rifampin. Drug Metab. Rev. 12:159-218.
9. Kerbusch, T., U. Wahlby, P. A. Milligan, and M. O. Karlsson. 2003. Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability. Br J. Clin. Pharmacol. 56:639-652.
10. Keung, A., K. Reith, M. G. Eller, K. A. McKenzie, L. Cheng, and S. J. Weir. 1999. Enzyme induction observed in healthy volunteers after repeated administration of rifapentine and its lack of effect on steady-state rifapentine pharmacokinetics: part I. Int. J. Tuberc. Lung Dis. 3:426-436.
11. Keung, A., M. G. Eller, K. A. McKenzie, and S. J. Weir. 1999. Single and multiple dose pharmacokinetics of rifapentine in man: part II. Int. J. Tuberc. Lung Dis. 3:437-444.
12. Keung, A. C., R. C. Owens, Jr., M. G. Eller, S. J. Weir, D. P. Nicolau, and C. H. Nightingale. 1999. Pharmacokinetics of rifapentine in subjects sero-positive for the human immunodeficiency virus: a phase I study. Antimicrob. Agents Chemother. 43:1230-1233.
13. Keung, A. C., M. G. Eller, and S. J. Weir. 1998. Single-dose pharmacokinetics of rifapentine in women. Pharmacokinet. Biopharm. 26:75-85.
14. Keung, A. C., M. G. Eller, and S. J. Weir. 1998. Single-dose pharmacokinetics of rifapentine in elderly men. Pharm. Res. 15:1286-1291.
15. Keung, A. C., M. G. Eller, and S. J. Weir. 1998. Pharmacokinetics of rifapentine in patients with varying degrees of hepatic dysfunction. J. Clin. Pharmacol. 38:517-524.
16. Langdon, G., J. J. Wilkins, P. J. Smith, and H. McIlleron. 2004. Consecutive-dose pharmacokinetics of rifapentine in patients diagnosed with pulmonary tuberculosis. Int J. Tuberc. Lung Dis. 8:862-867.
17. Rastogi, N., K. S. Goh, M. Berchel, and A. Bryskier. 2000. Activity of rifapentine and its metabolite 25-O-desacetylrifapentine compared with rifampicin and rifabutin against Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis and M. bovis BCG. J. Antimicrob. Chemother. 46:565-570.
18. 14C-rifapentine in healthy volunteers. Drug Metab. Dispos. 26:732-738.
19. Schuetz, E. G., A. H. Schinkel, M. V. Relling, and J. D. Schuetz. 1996. P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc. Natl. Acad. Sci. USA 93:4001-4005.
20. Sheiner, L. B., and S. L. Beal. 1998. NONMEM users guide, part V. University of California, San Francisco.
21. Weiner, M, N. Bock, C. A. Peloquin, W. J. Burman, A. Khan, A. Vernon, Z. Zhao, S. Weis, T. R. Sterling, K. Havden, S. Goldberg, and the Tuberculosis Trials Consortium. 2004. Pharmacokinetics of rifapentine 600, 900 and 1,200 mg during once-weekly tuberculosis therapy. Am. J. Respir. Crit. Care Med. 169:1191-1197.
22. Wilkins, J. J. 2005. NONMEMory: a run management tool for NONMEM. Comput. Methods Programs Biomed. 78:259-267.